Gamida Cell Announces 2019 Goals and Provides Company Update

San Francisco, CA, January 07, 2019 --( Gamida Cell Ltd. (Nasdaq:GMDA), a leading cellular and immune therapeutics company, reported expected milestones for 2019, which highlight the company's progress advancing its clinical development candidates: NiCord®, an investigational universal bone marrow donor source in late-stage development for patients with hematologic malignancies (blood cancers), and NAM-NK, an investigational, cell-based cancer immunotherapy in development in patients with non-Hodgkin lymphoma and multiple myeloma. VIEW FULL PRESS RELEASE


Popular posts from this blog

Publish your press release on every network simultaneously for the best possible reach. Distribute through PRweb, Cision & PRNewswire and over 1000 news networks.